Novartis's Odomzo set for EU approval in BCC
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted a positive opinion to Novartis's anticancer Odomzo (sonidegib), for approval in adults with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.